OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 10 of 33

11 Some Drug Interactions Contraindications • During or within 14 days following monoamine oxidase (MAO) inhibitors, sympathomimetics, alcohol, adrenergic neuron blocking drugs, and possibly some anesthetic agents • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see Precautions) • Nursing (see Precautions) • Known hypersensitivity or idiosyncrasy to the sympathomimetic amines • May alter the exposure to oral contraceptives, causing irregular menstrual bleeding but not an increased risk of pregnancy • Oral contraceptives should not be discontinued if spotting occurs. • May potentiate central nervous system depressants such as alcohol Patients should avoid concomitant alcohol. • May potentiate hypokalemia of non-potassium-sparing diuretics • Phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis. • Age <12 years • Pregnancy • Glaucoma • Uncontrolled hyperthyroidism • During or within 14 days of taking monoamine oxidase inhibitors • Hypersensitivity or idiosyncrasy to sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024